Erasca
Yahoo Finance • 4 days ago
Erasca to Present at the 8th Annual Evercore Healthcare Conference
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story
Yahoo Finance • 10 days ago
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment... Full story
Yahoo Finance • 16 days ago
3 Promising Penny Stocks With Market Caps As Low As $200M
As the Dow Jones Industrial Average reaches new heights, closing above 48,000 for the first time amid optimism about an end to the U.S. government shutdown, investors are keenly observing market dynamics that may influence their portfolios... Full story
Yahoo Finance • 17 days ago
Erasca Reports Third Quarter 2025 Business Updates and Financial Results
U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phas... Full story
Yahoo Finance • 3 months ago
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
[Wall Street New York stock exchange stock market] alexsl Erasca (NASDAQ:ERAS [https://seekingalpha.com/symbol/ERAS]), Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]), and Xencor (NASDAQ:XNCR [https://seekingalpha... Full story
Yahoo Finance • 4 months ago
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, a... Full story
Yahoo Finance • 6 months ago
Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven c... Full story
Yahoo Finance • 7 months ago
Erasca Reports First Quarter 2025 Business Updates and Financial Results
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash e... Full story
Yahoo Finance • 7 months ago
Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Erasca Inc. (NASDAQ:ERAS) stands against other biotech penny stocks. Peter Marks’s dep... Full story
Yahoo Finance • 8 months ago
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach... Full story
Yahoo Finance • 8 months ago
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H... Full story
Yahoo Finance • 10 months ago
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story
Yahoo Finance • 2 years ago
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801... Full story
Yahoo Finance • 2 years ago
Erasca to Present at Upcoming Investor Conferences in November
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story
Yahoo Finance • 2 years ago
Erasca to Present at the Cantor Global Healthcare Conference
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story
Yahoo Finance • 2 years ago
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven... Full story
Yahoo Finance • 2 years ago
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in Q2-Q4 2024 Dosing of first patient in... Full story
Yahoo Finance • 2 years ago
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasda... Full story
Yahoo Finance • 3 years ago
Erasca Further Strengthens Business Leadership with Two Key Promotions
David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer Nik Chetwyn, Ph.D., previously Erasca’s SVP of Operations, has been promoted to... Full story
Yahoo Finance • 3 years ago
Erasca Reports First Quarter 2023 Financial Results and Business Updates
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1 2024; dosing of the first patient in Phas... Full story
